Gene-editing tech firm Inscripta has made the strategic acquisition of life sciences company Solana Biosciences for an undisclosed sum. The deal is expected to close in early 2018, according to a press release from the company.
Gene-editing tech firm Inscripta has made the strategic acquisition of life sciences company Solana Biosciences for an undisclosed sum. The deal aims to speed up the commercialisation of Inscripta's CRISPR-based gene-editing technology tools, and will see Solana CEO Tom Rosso – a former Illumina executive – become VP of operations.